"Will this affect my child's growth?" It's the question every parent of an adolescent asks, and it deserves a thorough answer. Adolescence is a period of rapid development: height, bone density, hormonal maturation, and brain development all depend on adequate nutrition and metabolic health.
Here's what the current research tells us about GLP-1 medications and adolescent development.
Height and linear growth
The STEP TEENS trial (the largest clinical trial of semaglutide in adolescents) monitored height velocity throughout the 68-week study period. The findings were reassuring:
Adolescents treated with semaglutide continued to grow in height at rates consistent with their developmental stage. No clinically significant difference in height velocity was observed between the treatment and placebo groups.
This makes biological sense. GLP-1 medications primarily affect appetite signaling and metabolic pathways. They don't directly interfere with growth hormone or the growth plates responsible for height development.
However, adequate nutrition remains essential for growth. This is why pediatric GLP-1 programs must include nutritional monitoring to ensure caloric and protein intake supports ongoing development, even as appetite decreases.
Bone density
Adolescence is a critical period for bone mineral accrual. Roughly 90% of peak bone mass is achieved by age 18. Any intervention that reduces caloric intake raises the question of bone health.
Current evidence suggests:
Thryvwell's clinical team monitors bone health markers and ensures nutritional intake supports skeletal development throughout treatment.
Wondering if this applies to your child? The 2-minute eligibility check tells you if Thryvwell could be a fit. No commitment, no payment info.
Puberty and hormonal development
Obesity itself can disrupt pubertal timing, often accelerating puberty in girls and potentially delaying it in boys. By addressing obesity, GLP-1 treatment may actually help normalize hormonal development rather than disrupt it.
Key considerations:
Why pediatric-specific monitoring matters
Adult weight management programs don't track growth velocity, bone accrual, or pubertal staging because adults aren't developing. Adolescents are. This is why treatment through a pediatric-focused program is essential:
This level of monitoring isn't standard in adult telehealth programs. It's one of the reasons a pediatric-specific approach exists.
Sources
- Weghuber, D. et al. "Once-Weekly Semaglutide in Adolescents with Obesity." NEJM (2022). Growth velocity data
- Golden, N.H. et al. "Optimizing Bone Health in Children and Adolescents." Pediatrics (2014)
- Reinehr, T. "Obesity and Puberty." Best Practice & Research Clinical Endocrinology (2022)
Designed for young bodies
Thryvwell's clinical team monitors growth and development at every step of treatment
The information on this page is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment.
